1,720,962 research outputs found
Bhanga as an activity potentiater in Ayurvedic classics and Indian alchemy (Rasashastra): A critical review
No full textBhavana (impregnation) and Swedana (boiling) are the processes used in Ayurvedic pharmacy for preparation of formulations containing the drugs of metallic, mineral and poisonous origin to make them safe and potent for internal administration. Drugs of herbal origins are primely used for the Bhavana process. Bhanga(Cannabis sativa Linn.) a drug with great medicinal potency has been highlighted for its Deepana(digestive stimulant), Pachana(digestive), Ruchya (Taste promoter), Madakari (intoxicant),Vyavayi(short acting),Grahi(withholds secretions),Medhya (memory booster), Rasayana (adapto-immuno-neuro-endocrino-modulator) activities were used as a processing media in many formulations. In 19th century, it is included in narcotic group of plants and its use, as a drug, has been restricted. In 21st century again, the drug is gaining attraction from scientific communities due to its wide pharmacological properties. However, there is no collective information available at a glance regarding the use of Bhanga in various processing techniques of classical formulations. Hence, it is the need of the time to present the comprehensive information on cannabis, as quoted in classical texts with probable research co-relation, so as to bring the drug again in to limelight. The present review aims to compile all the information about the use of cannabis as a activity potentiater so that it can be further practically utilized in pharmaceutics and clinics with legal permissions. A thorough review, from available 41 Rasagranthas (text related to Indian alchemy) and 26 classical texts was carried out to compile the information about formulations where Bhanga is used as process media. The review shows that; Bhanga has been used, as a pharmaceutical processing agent, in 157 formulations being indicated in 40 different disease conditions. Among them, in 154 formulations, it is used as Bhavana media and in 3 formulations as a Swedana media. The present observation could help the future researchers to explore the drug for therapeutic utilities
Role of Deepaneeya and Shwashara Dashemani in the Management of Tamakashwasa w.s.r. to Bronchial Asthma: a review
Full text linkAccording to Global initiative for Asthma workshop 2005 report, there will be additional 100 millions of people suffering from asthma by 2025. Sushruta has quoted; Shwasa a disease described in Ayurvedic classics is more akin to bronchial asthma. Madhavakara has mentioned Agnimandya as root cause of all diseases. Aacharyas have included Pranavaha, Annavaha and Udakavaha Strotasa vitiation in the etiopathogenesis of Shwasa. Charaka has described the treatment of Shwasa according to its Karanas (etiological factors), Sthana (organ of manifestation) and Moola (root place of pathogenesis). Aamashaya has been referred as an Udbhavasthan of Shwasa by Vagbhata and Charaka. Chakrapani explains Aamashaya as Pittasthana (Agni) indicating importance of management of Agnimandya (hypofunction of Agni). Deepaneeya Dashemani acts on the Moolasthana of Strotasa involved in Shwasa. Deepaneeya Dashemani described by Charaka includes Pippali, Pipplaimoola, Chavya, Chitraka, Shunthi, Amlavetasa Maricha, Ajmoda, Bhallatakasthi and Hingu. Out of these; nine Dravyas possess Katu Rasa except Amlavetasa. All Dravyas have Ushna Veerya, Laghu and Teekshna Gunas. Most of them possess Katu Vipaka and acts as Deepana, Pachana and Strotovishodhana. Out of ten, two Dravyas Amlavetasa and Hingu are common to Deepaneeya and Shwashara Dashemani. Research studies have reported bronchodilator, antiasthmatic, antiallergic, antibacterial, antitussive and antihistaminic actions of these drugs
Role of Withaferin A in the management of breast cancer: A comprehensive review
Full text linkBackground: Breast cancer is one of the leading causes for cancer mortality. The conventional treatments are being rprted for many side effects which affects quality of life of a patient. Novel therapeutic and preventative strategies from the medicinal herbs are needed to reduce suffering, disease free survival, and mortality from breast cancer. Withania somnifera L. Dunal (Indian winter cherry or Ashwagandha) from the Solanaceae family is an appealing medicinal plant widely investigated for its breast cancer potential. Ayurveda treaties explained various formulations using root of Ashwagandha. Modern science explained uses of root and leaf in extract forms. Withaferin A is a promising anticancer withanolides. This review is based on in-vitro researches of Withaferin A on breast cancer cell lines like MCF-7 cells, MDA-MB-231, SUM159, MDA-MB-468, SUM149,SUM159, 231MFP supported by its mechanism, in-vivo studies and clinical records. Material and methods: This review is based on various preclinical researches related to breast cancer. Moreover, this review represents the effect of Withaferin A on cancer cell. Various articles including studies and description of Ashwagandha were reviewed using databases namely Google Scholar, PubMed, Web of Science, Scopus. Result:Withaferin A significantly arrests the growth of many breast cancer cell in vivo and in vitro. Conclusion: Ashwagandha is a commonly available, cost effective natural medicine,possess anti-cancer potential. It can serves a add on treatment strategy for breast cancer management, chemoprevention, tumor suppression
Going Beyond Counting First Authors in Author Co-citation Analysis
Full text linkThe present study examines one of the fundamental aspects of author co-citation analysis (ACA) - the way co-citation
counts are defined. Co-citation counting provides the data on which all subsequent statistical analyses and mappings
are based, and we compare ACA results based on two different types of co-citation counting - the traditional type that
only counts the first one among a cited work's authors on the one hand and a non-traditional type that takes into
account the first 5 authors of a cited work on the other hand. Results indicate that the picture produced through this non-traditional author co-citation counting contains more coherent author groups and is therefore considerably clearer. However, this picture represents fewer specialties in the research field being studied than that produced through the traditional first-author co-citation counting when the same number of top-ranked authors is selected and analyzed. Reasons for these effects are discussed
Variations on the Author
Full text link“Variations on the Author” discusses two of Eduardo Coutinho’s recent films (Um Dia na Vida, from 2010, and Últimas Conversas, posthumously released in 2015) and their contribution to the general question of documentary authorship. The director’s filmography is characterized by a consistent yet self-effacing form of authorial self-inscription: Coutinho often features as an interviewer that rather than express opinions propels discourses; an interviewer that is good at listening. This mode of self-inscription characterizes him as an author who is not expressive but who is nonetheless markedly present on the screen. In Um Dia na Vida, however, Coutinho is completely absent form the image, while Últimas Conversas, on the contrary, includes a confessional prologue that moves the director from the margins to the center of his films. This article examines the ways in which these works stand out in the filmography of a director who offers new insights into the notion of cinematic authorship
Appropriate Similarity Measures for Author Cocitation Analysis
Full text linkWe provide a number of new insights into the methodological discussion about author cocitation analysis. We first argue that the use of the Pearson correlation for measuring the similarity between authors’ cocitation profiles is not very satisfactory. We then discuss what kind of similarity measures may be used as an alternative to the Pearson correlation. We consider three similarity measures in particular. One is the well-known cosine. The other two similarity measures have not been used before in the bibliometric literature. Finally, we show by means of an example that our findings have a high practical relevance.information science;Pearson correlation;cosine;similarity measure;author cocitation analysis
Phytoestrogen: A protective shield for post-menopausal symptoms and breast cancer risk
Full text linkMenopause is a physiological unavoidable condition in women’s life which leads to vasomotor, psychological, urogenital and chronic diseases collectively termed as post-menopausal symptoms (PMS). Hormone replacement therapy (HRT) is conventional line of treatment for treating PMS in which estrogens replacement is major choice for better therapeutic efficacy against symptoms like hot flushes, osteoporosis, hormonal balances, insomnia, obesity etc. However, estrogen is reported risk factor for breast cancer. The review discusses Ayurveda based strategies for management of PMS with phytoestrogen herbs, diet, lifestyle modification, de-addiction measures, yoga, aroma therapies etc. supported by evidence-based documentation.Herbs namely Dhanyaka (Coriander sativum), Manjishtha (Rubia cordifolia L), Chandana (Santalum album L), Ashwagandha (Withania somnifera L. Dunal), Jatamansi (Nardostachys jatamansi DC), Shatavari (Asparagus racemosus L), Kumari (Aloe vera L), Yashtimadhu (Glycyrrhiza glabra L), Haridra (Curcuma longa L), Triphala (Combination of fruits of Haritaki, Bibhitak, Amalaki in the proportion 1:2:4), Gokshura (Tribulus terrestris L), Arjuna (Terminalia Arjuna L.), Guduchi (Tinospora cordifolia L.), Ela (Elettaria cardamomum L), Narikela (Coccus nucifera L), Masha (Phaseolus vulgaris L), Mudga (Vigna radiata L). Shunthi (Zinziber officinale Roxb), Methika (Trigonella foenumgraecum L), Tila (Sesamum indicum L) are the natural sources of phytoestrogens. Phytoestrogen don’t exert side effects like synthetic estrogen molecules. These herbs are useful for management of various symptoms of PMS. Having anti-cancer potential against breast carcinoma these are useful for prevention of risk of breast cancer
Dispelling the Myths Behind First-author Citation Counts
Full text linkWe conducted a full-scale evaluative citation analysis study of scholars in the XML research field to explore just how different from each other author rankings resulting from different citation counting methods actually are, and to demonstrate the capability of emerging data and tools on the Web in supporting more realistic citation counting methods. Our results contest some common arguments for the continued
use of first-author citation counts in the evaluation of scholars, such as high correlations between author rankings by first-author citation counts and other citation
counting methods, and high costs of using more realistic citation counting methods that are not well-supported by the ISI databases. It is argued that increasingly available digital full text research papers make it possible for citation analysis studies to go beyond what the ISI databases have directly supported and to employ more
sophisticated methods
- …
